Welcome to our dedicated page for Novo-Nordisk A/S SEC filings (Ticker: NVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Novo Nordisk A/S (NVO) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as a foreign private issuer listed on the New York Stock Exchange. Novo Nordisk files reports on Form 6‑K that cover financial performance, pipeline progress, governance changes, and material corporate developments.
For a pharmaceutical preparation manufacturer focused on diabetes, obesity, and rare diseases, these filings are a key source of detail on GLP‑1 and semaglutide programs, including Wegovy injection and the Wegovy pill, as well as investigational assets such as CagriSema and cagrilintide. The 6‑K for the first nine months of 2025, for example, outlines sales growth in diabetes and obesity care, rare disease performance, R&D pipeline highlights, and strategic acquisitions in MASH and rare blood disorders.
Investors can also use Novo Nordisk’s filings to monitor capital markets and governance information. Recent 6‑Ks disclose insider transactions in Novo Nordisk B shares by board members and executives, the convening of an Extraordinary General Meeting to elect new board members, and subsequent changes in board leadership and committee composition. Other filings describe agreements with the US Administration on pricing and access for semaglutide medicines in Medicare and Medicaid, and an unsolicited proposal to acquire Metsera, Inc.
On Stock Titan, these filings are updated as they are released on EDGAR. AI‑powered summaries help explain lengthy financial reports and company announcements in plain language, highlighting items such as revenue drivers in diabetes and obesity care, progress in MASH and cardiovascular programs, and the potential impact of pricing agreements. Users can quickly scan Form 6‑K disclosures, identify insider share dealings, and understand how Novo Nordisk’s strategic decisions and R&D investments may shape its long‑term profile in diabetes, obesity, rare disease, and cardiometabolic medicine.
Novo Nordisk A/S reported insider dealings under Article 19 of the EU Market Abuse Regulation. The company disclosed transactions by David Moore, Executive Vice President, US Operations, in Novo Nordisk B shares.
On 2025-11-10, Moore completed two transactions: an acquisition of 18,634 shares at DKK 0.00 as part of a recruitment package (outside a trading venue), and a sale of 8,160 shares at DKK 297.95 on Nasdaq Copenhagen, for an aggregated amount of DKK 2,431,301.74. The instrument is identified as Novo Nordisk B (ISIN DK0062498333).
These disclosures are routine for board members and executives and are reported to enhance transparency around trading by persons discharging managerial responsibilities and their associated persons.
Novo Nordisk announced an agreement with the U.S. Administration to lower prices for semaglutide medicines, including Wegovy and Ozempic, and expand access in the U.S. starting in 2026. Coverage for anti-obesity medicines will be enabled in Medicare Part D through a pilot program designed to cover a majority of Part D beneficiaries. Prices will also be lowered in Medicaid and in the direct-to-patient cash channel, and the company is expected to receive a three-year tariff exemption.
Novo Nordisk currently expects an estimated direct, negative low single-digit impact on global sales growth in 2026. The company plans to provide its 2026 financial outlook alongside full-year 2025 results on 4 February 2026. Following this announcement, Novo Nordisk and the U.S. Administration will finalize the agreement’s details.
Novo Nordisk reported solid growth for the first nine months of 2025 while absorbing major restructuring costs and tightening its outlook. Net sales rose 12% in Danish kroner to DKK 229.9 billion, or 15% at constant exchange rates, driven mainly by Diabetes and Obesity care. Operating profit increased 5% to DKK 95.9 billion (10% at CER), but included around DKK 9 billion of one-off restructuring costs tied to a company-wide transformation; excluding these, operating profit would have grown 15% in kroner and 21% at CER. Net profit was DKK 75.5 billion, up 4%, and diluted EPS reached DKK 16.99.
Obesity care sales climbed 37% in kroner to DKK 59.9 billion (41% at CER), powered by Wegovy, while GLP‑1 diabetes products grew 10% at CER to DKK 114.7 billion. Rare disease sales rose 13% at CER to DKK 14.3 billion. The company is cutting about 9,000 of 78,400 positions and redirecting savings into growth areas.
Novo Nordisk now expects 2025 sales growth of 8–11% at CER and operating profit growth of 4–7% at CER, narrowing prior ranges and reflecting lower growth expectations for GLP‑1 treatments, ongoing transformation costs and recent acquisitions. The R&D pipeline advanced with an FDA approval for Wegovy in MASH, new cardiovascular indications for Rybelsus, multiple late‑stage obesity programmes and the planned acquisition of Akero Therapeutics to expand its MASH portfolio.
Novo Nordisk (NVO) announced an unsolicited proposal to acquire Metsera, Inc. The offer includes cash consideration of 56.50 USD per share, equal to an approximate aggregated equity value of 6.5 billion USD (approximate enterprise value of 6.0 billion USD), plus contingent value rights (CVRs) of up to 21.25 USD per share (an approximate aggregated value of up to 2.5 billion USD) tied to clinical and regulatory milestones.
The cash consideration would be paid at signing in exchange for non‑voting preferred stock representing 50% of Metsera’s share capital, and the CVRs would be issued at closing in exchange for the remaining shares. Novo Nordisk states that Metsera’s early and development‑stage incretin and non‑incretin peptide programs are complementary to its strategy in obesity and diabetes. The proposal is subject to review by Metsera’s board.
Novo Nordisk A/S called a fully electronic Extraordinary General Meeting to elect new members to the Board of Directors. The meeting will be held on 14 November 2025 at 14:00 CET.
The agenda proposes electing Lars Rebien Sørensen as Chair, Cees de Jong as Vice Chair, and Britt Meelby Jensen, Mikael Dolsten and Stephan Engels as board members, with Kasim Kutay continuing. Several current directors will not stand for election. All proposals may be adopted by a simple majority of votes.
Record date for participation and voting rights is 7 November 2025 at 23:59 CET. Registration and proxy deadlines are 10 November 2025 at 23:59 CET, and votes by correspondence must be received by 13 November 2025 at 09:00 CET. The Company’s share capital is
Novo Nordisk A/S will convene an Extraordinary General Meeting to elect new members of the Board of Directors on 14 November 2025. The decision follows dialogue with the Novo Nordisk Foundation about board composition; the Foundation holds the majority of votes. The Board concluded that electing new members via an EGM is in the best interest of the company and shareholders to provide clarity on future governance.
Chair Helge Lund, Vice Chair Henrik Poulsen, and independent directors Laurence Debroux, Andreas Fibig, Sylvie Grégoire, Christina Law and Martin Mackay will not stand for election at the EGM. Kasim Kutay (not independent) and employee‑elected members Elisabeth Dahl Christensen, Liselotte Hyveled, Mette Bøjer Jensen and Thomas Rantzau will remain on the Board.
Novo Nordisk will host an investor conference call at 15:00 CEST on 21 October 2025, with a dial‑in link available on the company’s investor website.
Novo Nordisk is implementing a global transformation to speed decision-making and redirect resources toward diabetes and obesity growth opportunities. The company intends to reduce about 9,000 roles of its ~78,400 positions (approximately 5,000 of those in Denmark) and expects to deliver DKK 8 billion of annualised savings by the end of 2026. Management will incur one-off restructuring costs of DKK 8 billion, and it updated its full-year 2025 operating profit growth outlook to 4–10% at constant exchange rates, down from the prior 10–16% outlook—about a 6 percentage point reduction versus the August outlook. The transformation is presented as a response to recent slowdown in growth and increased organisational complexity, with additional initiatives planned to improve focus, performance culture and cost efficiency.
Novo Nordisk A/S filed a report showing trading in its American Depositary Receipts (ADRs) by a member of the board of directors. Board member Christina Law purchased Novo Nordisk ADRs on the New York Stock Exchange.
The filing states that she carried out several purchases on 18 August 2025 at prices of DKK 349.06 for 952 ADRs, DKK 349.04 for 598 ADRs and DKK 349.03 for 800 ADRs. In total, this represents an aggregated volume of 2,350 ADRs for a total consideration of DKK 820,252.49, reported in accordance with European market abuse rules.
Novo Nordisk disclosed that Ludovic Helfgott, Executive Vice President, sold 12,000 Novo Nordisk B shares at DKK 326 per share on Nasdaq Copenhagen on 2025-08-08, for an aggregate amount of DKK 3,912,000. The company reported the transaction under Article 19 of Regulation No. 596/2014, with the sale recorded as an initial notification by the named executive.
The announcement also reiterates basic company information: Novo Nordisk markets its B shares on Nasdaq Copenhagen and ADRs on the New York Stock Exchange under the ticker NVO, employs about 78,400 people, and sells products in roughly 170 countries.
Form 6-K insider transaction report
On 8 Aug 2025, Novo Nordisk A/S (NVO) disclosed a managerial transaction under EU Market Abuse Regulation Article 19. Executive Vice President Ludovic Helfgott sold 28,710 class B shares (ISIN DK0062498333) on Nasdaq Copenhagen on 7 Aug 2025 at DKK 295.00 per share, generating gross proceeds of DKK 8,469,450.
The filing contains no financial results, strategic updates or additional insider dealings; it solely records this single transaction. Accordingly, investors receive limited insight into current operating performance, and the trade’s materiality is modest relative to Novo Nordisk’s market capitalisation.